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A GSK-3b modulator delays photoreceptor cell death and 
preserves visual function in the rd10 mouse model of retinitis 
pigmentosa
Catalina Hernandez- Sanchez1, Beatriz Villarejo1, Josefa Zaldivar2, 
Miguel Marchena1, Carmen Gil2, Pedro de la Villa3, Ana Martínez2, 
Enrique J. De La Rosa1. 1Molecular and Cellular Medicine, Centro 
De Investigaciones Biologicas (CSIC), Madrid, Spain; 2Chemical 
and Physical Biology, Centro de Investigaciones Biológicas, Madrid, 
Spain; 3Universidad de Alcalá de Henares, Alcalá de Henares, Spain.
Purpose: Retinitis pigmentosa (RP) is a heterogeneous group of 
inherited retinal dystrophies that lead to blindness. Photoreceptor cell 
death, reactive gliosis and retinal inÀammation are common features 
in animal models of the disease. The enzyme Glycogen Synthase 
Kinase-3 Beta (GSK-3β) is involved in inÀammatory processes 
associated to diverse neurodegenerative pathologies. The aim of 
our study is to test in the rd10 mouse whether the GSK-3β inhibitor 
VP3.15 (a small heterocyclic molecule) is a potential therapeutic 
treatment for RP.
Methods: Ex vivo studies: rd10 retinas at postnatal day 23 (P23) 
were placed in organotypic culture and treated with the VP3.15 
GSK-3β modulator. Photoreceptor cell death was analyzed TUNEL. 
In vivo studies: VP3.15 was injected intraperitoneally into rd10 mice 
from P15 to P45. Visual function was evaluated by ERG recording 
and retinal structure was visualized by immunohistochemistry 
in cryosections. The expression of pro-inÀammatory genes was 
analyzed by RT-qPCR.
Results: The GSK-3β inhibitor decreased by 50% photoreceptor cell 
death ex vivo. Moreover, intraperitoneal administration of VP3.15 
to rd10 mice preserved photoreceptor cell number and prevented 
microglial in¿ltration at P23, decreased pro-inÀammatory TNF-α and 
IL-1β, as well as GFAP gene expression at P23, and improved visual 
function up to P46.
Conclusions: GSK-3β inhibitors may constitute a therapeutic 
strategy for the treatment of Retinitis Pigmentosa.
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Flibanserin, a FDA approved dual serotonin receptor agonist-
antagonist, provides retinal neuroprotection from light induced 
damage
Aaron Coyner1, Renee C. Ryals1, Cristy A. Ku1, Rachel C. Patel1, 
Cody Fischer1, Yuquan Wen2, Rene Hen3, Mark E. Pennesi1. 1Oregon 
Health & Science University, Portland, OR; 2Baylor Visual Function 
Center, Baylor University Medical Center, Dallas, TX; 3Department 
of Pharmacology, Columbia University, New York, NY.
Purpose: We assessed the neuroprotective effects of Flibanserin 
(BIMT-17, Addyi), a dual 5-HT1A agonist and 5-HT2A antagonist, in a 
light-induced retinopathy mouse model.
Methods: Albino BALB/c mice and 5-HT1A KO mice were injected 
intraperitoneally with either vehicle (to serve as controls) or doses of 
Àibanserin ranging from 0.75 mg/kg to 15 mg/kg. Naïve controls did 
not receive any injections or light damage. Mice were administered 
a single injection of Àibanserin immediately before light damage or 
received a ¿ve-day treatment course at 48, 24, and 0 hours before 
light damage and 24 and 48 hours after light damage. Exposing 
vehicle injected mice to 10,000 lux of uniform light for one hour 
resulted in light-induced retinopathy. Seven days after light damage, 
spectral domain optical coherence tomography (SD-OCT) was used 
to assess retinal structure and electroretinography (ERG) to assess 
retinal function.
Results: A ¿ve-day treatment course of 3 mg/kg, 6 mg/kg, 9 mg/kg 
and 15 mg/kg Àibanserin signi¿cantly preserved outer retinal 
structure and function in a dose dependent manner compared to 
the vehicle group (p<0.05, ANOVA). A single administration of 
15 mg/kg Àibanserin completely protected mouse retinas from light-
induced retinopathy. Outer retinal thickness and function of the 15 
mg/kg Àibanserin group were not signi¿cantly different from the 
naïve group (p>0.05, ANOVA). Interestingly, a single 15 mg/kg dose 
of Àibanserin injected immediately prior to light damage completely 
protected 5-HT1A KO mouse retinas both structurally and functionally 
from light-induced retinopathy.
Conclusions: Multiple administrations of Àibanserin at doses equal 
to 3 mg/kg or greater can provide partial neuroprotection, while a 
dose of 15 mg/kg can provide full neuroprotection. Flibanserin is 
a fast acting drug that can elicit neuroprotection when delivered 
immediately before light damage. Dosing 5-HT1A KO mice with 15 mg/kg of Àibanserin did not lead to a reduction in neuroprotection, 
suggesting that Àibanserin’s neuroprotective effects are not mediated 
exclusively through 5-HT1A, but potentially through 5-HT2A as well.
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Creatine protects rat retinal neurons in an in vitro model of 
metabolic compromise
Paul Ikgan Sia2, 1, John P. Wood1, 2, Glyn Chidlow1, 2, 
Robert J. Casson1, 2. 1South Australian Institute of Ophthalmology, 
Adelaide, SA, Australia; 2Department of Ophthalmology and Visual 
Sciences, University of Adelaide, Adelaide, SA, Australia.
Purpose: There is increasing interest in creatine as a potential 
agent to provide neuroprotection. Our study aimed to investigate 
the effect of prophylactic creatine on cultured retinal cells subjected 
to mitochondrial electron transport chain inhibition as a model of 
metabolic and energetic dysfunction.
Methods: Mixed rat retinal cultures comprising neurons and glia 
were established and treated at six days in vitro with a range of 
creatine concentrations (no creatine controls, 0.1mM, 0.5mM, 
1.0mM, and 5.0mM) for 24 hours. Subsequent to this, half of each 
group was subjected to a 1-hour or a 24-hour incubation with sodium 
azide (10mM, N=12; and 1mM, N=4 respectively). Cells were then 
¿xed and processed for immunocytochemistry. Antibodies labelling 
distinct neuronal populations (Calretinin and GABA) were used for 
quanti¿cation of viable cells in each group. Furthermore, potential 
mechanisms of protection were also investigated by assessing 
apoptosis (TUNEL assay) and levels of adenosine triphosphate 
(ATP). One-way ANOVA followed by Tukey multiple-comparison 
test was used for statistical analysis.
Results: 1-hour and 24-hour incubations with sodium azide resulted 
in losses of up to 85% and 98% respectively for both Calretinin-
immunoreactive (IR) and GABA-IR neurons. In the 1-hour 
azide-treated group, prophylactic treatment of creatine at >0.5mM 
